Please join us in thanking one colleague and welcoming another as CP3 announces a new Associate Director.
Dr. Katie Suda will be stepping out as CP3's Associate Director to devote more time to her expanding portfolio of drug shortages research. Katie has helped lead CP3 with vision and dedication for many years, and she has built one of the field's most prominent research programs on drug shortages. Her team studies why shortages occur, how to predict them, and what mitigation strategies can prevent them. That work includes an AHRQ-funded study of how COVID-19 disrupted drug supply chains in the U.S. and Canada, a new NIH R01 (SUPPLY-US) to strengthen U.S. pharmaceutical supply chains and develop an At-Risk Medicine List for health systems, and an NIH R13 award to launch the first national conference series dedicated to drug shortages. Her findings have been published in JAMA and JAMA Network Open, and she is a sought-after voice on topics ranging from drug supply to antibiotic stewardship. We are deeply grateful to Katie for her years of leadership at CP3, and we look forward to her continuing contributions to the Center.
Dr. Tim Anderson will succeed Katie as Associate Director of CP3. Tim leads the Prescribing Wisely Lab, which focuses on improving the safety, value, and appropriateness of prescribing. His recent work has earned national attention. Earlier this year, Tim led a JAMA study showing that more than half of U.S. adults ages 30 to 79, about 87.5 million people, are now recommended for statins under updated cardiovascular guidelines. Tim also served on the committee that wrote those guidelines. He has been interviewed by outlets including the New York Times, STAT, and TribLIVE on a wide range of prescribing and deprescribing topics, and he is becoming a nationally recognized expert in cardiovascular prevention and prescribing. In addition, he serves as an Associate Editor of JAMA Internal Medicine and the director of the Pitt General Internal Medicine Clinician-Researcher Fellowship. We thank Tim for his willingness to take on this new role at CP3.